- 2016 – : Professora Auxiliar (15%), ISCTE-IUL
- 2016 – : Docente Livre, Faculdade de Medicina da Universidade de Lisboa (FMUL)
- 2015 – : Group Leader, Instituto de Medicina Molecular (IMM), FMUL
- 2014 - : Professora Auxiliar Visitante, Centre for Neuroimaging Sciences, Institute of Psychiatry (IoP), King's College of London (KCL).
- 2012 – 2014: Professora Auxiliar, Coordenadora de módulo de MSc, Dep. Psychosis Studies, IoP, KCL.
- 2011 – 2014: Pós-doc fellow, UK National Institute for Health Research (NIHR), IoP, KCL - "Construção de um biomarcador multimodal para prever o início da psicose".
- 2008 – 2010: Investigadora Pós-Doc for Optimal Medicine, Ltd & IoP, KCL, joint-venture - "Genética e farmacognética da resposta de pacientes com psicose à medicação antipsicótica".
- 2004 – 2008: Doutoramento em Neuroimagiologia Genética - "Efeito de genes reguladores da dopamine na activação regional functional durante a fluência verbal na saúde e na esquizofrenia", Secção de Genética & Secção de Neuroimagiologia do Dep. Psychological Medicine, IoP, KCL. Orientador: Prof. David Collier.
- 2002 - 2003: Estagiária Leonardo Da Vinci - "Genes candidatos dos distúrbios alimentares, IoP, KCL. Orientador: Prof. David Collier.
- 2001 - 2002: Residente Erasmus em genética e biotecnologia no Mediterranean Agronomic Institute of Chania (MAICh).
- 1997 - 2002: Licenciatura em Biologia, Faculdade de Ciências da Universidade de Lisboa.
Our interest is the molecular biology of human behaviour, which we aim to translate into improving etiological and therapeutic models of neuropsychiatric disorders. We have reported on the influence of genetic variations on: mental illness risk, brain function/structure and drug treatment response.
We are dedicated to: 1) understanding the role of oxytocin in social cognition, and its relevance to psychosis, autism and anorexia nervosa; and 2) building clinically useful multimodal biomarkers for aiding clinical diagnostic and prognostic predictions. For this, we combine psychological and neuropharmacological experimentation with (epi)genetics, neuroimaging and psychophysiological tools – which is made possible by a diverse team of biophysics engineers, psychologists, biologists and medical doctors.
Áreas de Investigação
- Genética Neuroimagiológica
- Genética Molecular
- Neuroimagiologia de Ressonância Magnética
- Cognição Social
- Teoria da Mente
- Dilema do Prisioneiro
- Fluência Verbal
- Matéria branca
- Interacção Gene x Ambiente
Equipa de Investigação
Projectos de Investigação em Curso
If you would like to do research (e.g. as MSc, PhD student or Post-Doc) in the context of one of the 3 projects streams below, and have a degree in biomedical engineering, statistics, computational modeling/bioinformatics, medicine, biology, psychology, or related fields, email email@example.com.
Project Stream 1. The Neurobiology of Social Cognition.
Keywords. Oxytocin, dopamine, genetics, neuropharmacology, neuroimaging, cognitive empathy, theory-of-mind, trust, cooperation, reward, reinforcement learning, mirror neurons, emotion recognition, anorexia nervosa, schizophrenia.
Context. Understanding the neurochemistry and circuitry mediating social cognition is key to treat a large range of neuropsychiatric disorders – as social deficits are often present at their origin and often do not subside with treatment. Working out what others think, intend and feel (i.e. cognitive empathy or theory-of-mind) is essential for optimal communication and cooperation and is dysfunctional in schizophrenia, borderline personality disorder, drug addiction, anorexia nervosa, and autism, among others. We are characterizing what molecules and brain pathways are involved in social cognition, for example: how does oxytocin promote cognitive empathy? Where does it act? What effect does it have in brain and sympathetic function? How does it interact with other neurotransmitter systems?
Tools. We will study healthy humans and patients with structural and functional neuroimaging (MRI, DTI and MRS), double blind placebo-controlled pharmacological and TMS administration, psychological testing, social cognition tasks, eye-tracking, pupilometry, skin conductance, EEG, DNA testing and computational modelling. We use mainly MATLAB, SPSS, and other more specific quantitative data analysis and task presentation software.
Collaborations. King’s College London (UK), Emory University (USA), IST (Portugal), ISCTE (Portugal), FPUL (Portugal), Champalimaud Neuroscience (Portugal), ISPA (Portugal), and The Netherlands Institute for Neuroscience (The Netherlands).
Project Stream 2. Multimodal biomarkers to predict the onset and prognosis of neuropsychiatric illnesses.
Keywords. Genetics, neuroimaging, environment, clinical biomarkers, schizophrenia, autism, Alzheimer’s, Parkinson’s.
Context. Psychiatry and, to a lesser extent, neurology are still fields of medicine that take very little advantage of quantitative, biological and objective measurements – with a lot of trial-and-error and one-size-fits-all therapeutics. This may be why diagnosis, prediction of prognosis and response to treatment are relatively inaccurate, late and expensive. For example, about a third of Alzheimer’s cases go on mis- or under-diagnosed; it is still undetected which one third of people with at-risk symptoms for schizophrenia go on to develop this chronic illness, and about one quarter of schizophrenia patients do not respond to their first line of treatment. Can we capitalize on the existing information in brain scans and other quantitative measurements to assist clinicians in deciding on patients’ diagnosis or prognosis, earlier and more accurately than currently – so that the correct treatment can start as soon as possible?
Tools. We are developing pattern recognition algorithms that can statistically predict the level of personalized risk of each new patient. To train these algorithms, we use pre-existing samples (free online or our own) containing neuroimaging and also genetic, psychological, environmental and clinical data. We use mainly MATLAB and machine learning tools.
Collaborations. King’s College London (UK), IBEB-FCUL (Portugal), Radboud University Nijmegen (The Netherlands), University College London (UK).
Project Stream 3. Genetic underpinnings of human brain function and structure.
Keywords. Genetics, neuroimaging, environment, verbal fluency, white matter, grey matter, brain connectivity, dopamine synthesis, fMRI, sMRI, DTI, PET, schizophrenia, bipolar disorder, polygenic risk scores, GWAs.
Context. Several aspects of brain function and structure are known to be highly heritable but little is known about what specific genes contribute to them. For example, while specific genetic variations have been associated with cognitive abilities and susceptibility to many psychiatric illnesses, we still do not know how they operate or increase risk. How do genetic variations modulate executive function such as verbal fluency and risk of bipolar disorder and schizophrenia? We will investigate their impact directly on brain activation, anatomy and dopamine synthesis.
Tools. We will use an existing database of controls and bipolar disorder and schizophrenia patients, in whom MRI data (functional and structural MRI, Positron Emission Tomography (PET) and Diffusion Tensor Imaging –DTI) and genotyping (including genome-wide GWA) human data has been collected, to correlate genetic with neuroimaging measurements in healthy humans, and patients with schizophrenia and bipolar disorder. We mainly use MATLAB, SPM, FSL, free surfer and MIBCA software.
Collaborations. King’s College London (UK) and Oxford University Hospitals (UK).
2016 - 2018 Bial Psychophysiology grant, Bial Foundation (€50.000)
- 2016 – 2018 AstraZeneca/FMUL grant to team (Dr. Daniel Martins) (€5.000), AstraZeneca/FMUL –faculty-level, international peer-review.
- 2016 ‘InovPortugal New Ideas B2B’ award to Startup idea (7 awardees among >13000 competitors), Acredita Portugal, Portugal
- 2016-2019 Twinning Grant (€1.000.000) to European Consortium (DP as a member), H2020-TWINN-2015, 692340, by European Commission.
- 2016 – 2017 Breakthrough Idea Grant (€100.000), Instituto de Medicina Molecular, Portugal –institute-level, international peer-review.
- 2016 – 2020 PhD Fellowship to team (Dr. Vânia Tavares) by M2B Doctoral Programme (2016-2020), FCT, Portugal – institutional level, institutional peer-review.
- 2016 – 2020 PhD Fellowship to team (Dr. Sandro Nunes) SFRH/BD/112401/2015 (2016-2020), FCT, Portugal – national level, national peer-review.
- 2016 – 2020 PhD Fellowship to team (Dr. Daniel Martins) by LisbonBiomed Doctoral Programme (2016-2020), FCT, Portugal –institutional level, institutional peer-review.
- 2015 – 2020 FCT Investigator Starting Contract to PI IF/00787/2014, FCT, Portugal – national level, international peer-review.
- 2015-2020 FCT Exploratory Grant (€50.000) to PI, IF/00787/2014, FCT, Portugal.– national level, international peer-review.
- 2015 – 2019 EU Marie Curie Career Integration Grant to PI (FP7-PEOPLE-2013-CIG) (€100.000), international-level and peer-review.
- 2015 – 2016 Start-up Grant to PI (€30.000), Institute of Molecular Medicine, Portugal – institute-level, no peer review.
- 2013 – 2014 Academic Advancement Promotion to PI (grade 6-7 salary increase), KCL, UK, institute-level, institute peer-review.
- 2011 – 2014 Postdoctoral Fellowship to PI PDF-2010-03-047+£280,396+£49.920 grant, NIHR, UK, national-level and international peer-review.
- 2011 Brain travel award to PI (£500), Wellcome Trust Centre for Neuroimaging, UK– national-level and peer review.
- 2010 Harvard Medical School Travel award to PI ($1000), National Institute of Mental Health (NIMH), USA – international-level and peer review.
- 2009 Brain travel award to PI (£416), Wellcome Trust Centre for Neuroimaging, UK– national-level and peer review.
- 2008 Travel stipend to PI (£4000), University of Sichuan, China – institute-level, no peer-review.
- 2006 – 2008 7 Travel stipends to PI (total £3,907), Psychological Medicine, IoP, KCL, UK – institute-level, no peer-review.
- 2004 – 2008 PhD Fellowship to PI (SFRH/BD/12394/2003) (€133,080+€51,000), FCT, Portugal – national-level and peer-review.
- 2003 Junior Investigator Travel fellowship to PI ($1,250), Academy for Eating Disorders, USA – international-level and peer-review.
- 2002 – 2003 Leonardo Da Vinci fellowship to PI(£4,500), European Comission – university-level, no peer-review.
- 2001 – 2002 Erasmus fellowship to PI (€2.700), European Comission – university-level, no peer-review.
PI’s Internationally peer-reviewed and Pubmed-indexed N(published)=36, Citations N=1023, H-index =18
Mallas E; Carletti F; Chaddock C; Shergill S; Woolley J; Picchioni M; McDonald C; Toulopoulou T; Kravariti E; Bramon E; Murray R; Barker G; Prata D. The impact of CACNA1C gene, and its epistasis with ZNF804A, on white matter microstructure in health, schizophrenia and bipolar disorder. Genes, Brain and Behaviour. In press.
Martins D, Paloyelis Y, Prata D. “Shedding light on a dark question”: Peripheral oxytocin signalling and neurobehavioral responses to intranasal oxytocin in humans. Psychoneuroendocrinology. In press. IF:4.7
- Vassos E, Di Forti M, Coleman J, Iyegbe C, Prata D, Euesden J, O’Reilly P, Curtis C, Kolliakou A Patel H, Newhouse S, Traylor M, Ajnakina O; Mondelli V, Reis-Marques T, Gardner-Sood P, Aitchison K, Powell J, Atakan Z, Greenwood K, Smith S, Ismail K, Pariante C, Gaughran F, Dazzan P, Markus H; David A; Lewis C; Murray R, Breen G. An examination of polygenic score risk prediction in individuals with first episode psychosis. Biological Psychiatry. Priority Communication. In press. IF:10.2
- Mallas E, Carletti F, Chaddock C, Woolley J, Picchioni MM, Shergill S, Kane F, Allin M, Barker GJ, Prata DP. Genome-wide discovered psychosis-risk gene ZNF804A impacts on white matter microstructure in health, schizophrenia and bipolar disorder. PeerJ. 2016. 4:e1570; DOI 10.7717/peerj.1570.
- Bianconi F, Bonomo M, Marconi A, Kolliakou A, Stilo S, Iyegbe C, Muñoz P, Homayoun S, Mondelli V, Luzi S, Dazzan P,Prata D, La Cascia C, O’Connor J, David A, Morgan C, Murray R, Lynskey M, Di Forti M. Differences in Cannabis-related Experiences between Patients with a First Episode of Psychosis and Controls. Psychological Medicine. 2015. 16:1-9. IF:5.9
- Gurung R & Prata DP. What is the impact of genome-wide supported risk variants for schizophrenia and bipolar disorder on brain structure and function? A systematic review. Psychological Medicine. 2015. 10:1-20. IF:5.9
- Mechelli A, Prata D, Kefford C, Kapur S. Predicting clinical response in people at ultra-high risk for psychosis: A systematic and quantitative review. Drug Discovery Today. 2015. 20(8):924-7. IF:5.9.
- Ajnakina O, Borges S, DiForti M, Patel Y, Xu X, Green P, Ciufolini S, Paparelli A, Stilo S, Kolliakou A, Sood P, Marques TR, Sainz-Fuertes R, David AS, Prata DP, Mondelli V, Dazzan P, Powell J, Pariante C, Morgan C, Murray RM, Fisher HL, Iyegbe C. Role of Environmental Confounding in the Association between FKBP5and First-Episode Psychosis. Frontiers in Psychiatry.2014. 17;5:84.
- Prata DP, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neuroscience and Biobehavioural Reviews. 2014. 45:134-41. IF:9.4
- Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo S, Marconi A, La Cascia C, Reis-Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaugrhan F, David AS, Morgan C, Sthal D, Khondoker M, MaCabe R, Murray R. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin. 2014. Mar 19. [Epub ahead of print]. IF:8.5
- Bhattacharyya S, Iyegbe C, Atakan Z, Martin-Santos R, Crippa JA, Xu X, MD2, Williams S, Brammer M, Rubia K, Prata D, Collier DA, McGuire PK. Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. Psychological Medicine. 2014. 44(15):3315-28. IF:5.6
- Pettersson-Yeo W, Benetti S, Marquand AF, Dell’acqua F, Williams SC, Allen P, Prata D, McGuire P, Mechelli A. Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. Psychological Medicine. 2013. 43(12):2547-62. IF: 6.2
- Modinos G, Iyegbe C, Prata D, Rivera M, Kempton M, Valmaggia L, Sham P, van Os J, McGuire P. The candidate approach to gene-environment interactions in schizophrenia. Schizophrenia Bulletin. 2013. 150 (2-3): 356-65. IF:8.5
- Prata DP, Kanaan KA, Barker GJ, Shergill S, Woolley J, Georgieva L, Picchioni MM, Kravariti E, Walshe M, Allin M, Toulopoulou T, Bramon E, McDonald C, Giampietro V, Murray RM, Brammer M, O’Donovan M, McGuire PK. Risk variant of oligodendrocyte lineage transcription factor 2 is associated with reduced white matter integrity. Human Brain Mapping.2013. 34 (9):2015-31. IF: 7.1
- Pauli A, Prata DP, Mechelli A, Picchioni M, Fu CHY, Chaddock C, Kane F, Kalidindi S, McDonald C, Kravariti E, Toulopoulou T, Bramon E, Walshe M, Ehlert N, Georgiades A, Murray R, Collier D, McGuire P. Interaction between effects of genes coding for dopamine and glutamate transmission on striatal and parahippocampal function.Human Brain Mapping. 34 (9): 2244-58. IF: 7.1
- Radua J, Surguladze SA, Marshall N, Walshe M, Bramon E, Collier DA, Prata DP, Murray RM, McDonald C. The impact of CACNA1C allelic variation on effective connectivity during emotional processing in bipolar disorder. Molecular Psychiatry.2013; 18 (5): 526-7 IF: 14.0
- Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, Williams S, Brammer M, Collier DA, McGuire PK: Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: A preliminary report of the modulation of the effects of delta-9-THC on midbrain and striatal function by AKT1 and DAT1 genotypes. Molecular Psychiatry. 2012; 17 (12):1152-5. IF: 14.0
- Prata DP, Gafoor R, Kay V, Arranz M, Munro J, McGuire P. Dopaminergic genes influence early response to atypical antipsychotics in patients with first presentation of psychosis. Journal of Clinical Psychopharmacology. 2012;32(4):566-569. IF: 4.5
- Mechelli A, Prata D, Papagni SA, Tognin S, Kambeitz J, Fu C, Picchioni M, Walshe M, Toulopoulou T, Bramon E, Murray R, McGuire P. Genetic vulnerability to psychosis and cortical function: epistatic effects between DAAO and G72. Current Pharmaceutical Design. 2012;18(4):510-7. IF: 3.7
- Prata DP, Mechelli A, Fu C, Picchioni M, Kane F, Kalidindi S, McDonald C, Kravariti E, Toulopoulou T, Bramon E, Walshe M, Murray R, Collier DA, McGuire PK. Effect of D-amino acid oxidase activator (DAOA; G72) on brain function during verbal fluency. Human Brain Mapping. 2012; 33(1):143-153. IF: 7.1
- Papagni S, Mechelli A, Prata DP, Kambeitz J; Fu HY C, Picchioni M, Walshe M, Toulopoulou T, Bramon E, Murray R, Collier DA, Bellomo A, McGuire P. Differential effects of DAAO on regional activation and functional connectivity in schizophrenia, bipolar disorder and controls. Neuroimage. 2011; 56(4):2283-2291. IF: 6.7
- Prata DP, Mechelli A, Picchioni M, Fu C, Kane F, Kalidindi S, McDonald C, Kravariti E, Toulopoulou T, Bramon E, Walshe M, Murray R, Collier DA, McGuire PK. No association of Disrupted-in-Schizophrenia-1 variation with prefrontal function in patients with schizophrenia and bipolar disorder. Genes, Brain and Behaviour. 2011; 10(3):276-285 IF: 4.0
- Costafreda SG, Fu CH, Picchioni M, Toulopoulou T, McDonald C, Kravariti E, Walshe M, Prata D, Murray RM, McGuire PK. Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder. BioMed Central Psychiatry. 2011;11: No.18. IF: 2.3
- Baharnoori M, Bartholomeusz C, Boucher AA, Buchy L, Chaddock C, Chiliza B, Föcking M, Fornito A, Gallego JA, Hori H, Huf G, Jabbar GA, Kang SH, El Kissi Y, Merchán-Naranjo J, Modinos G, Abdel-Fadeel NA, Neubeck AK, Ng HP, Novak G, Owolabi OO, Prata DP, Rao NP, Riecansky I, Smith DC, Souza RP, Thienel R, Trotman HD, Uchida H, Woodberry KA, O’Shea A, Delisi LE. The 2nd Schizophrenia International Research Society Conference, 10-14 Apr 2010, Florence, Italy: Summaries of oral sessions. Schizophrenia Research. 2010; 124 (1-3):e1-e62. IF: 5.0
- Prata DP, Mechelli A, Picchioni M, Fu C, Toulopoulou T, Bramon E, Walshe M, Murray R, Collier DA, McGuire. Altered effect of dopamine transporter 3’UTR VNTR genotype on prefrontal and striatal function in schizophrenia. Archives of General Psychiatry. 2009; 66(11):1162-72. IF: 16.5
- Dutt A, McDonald C, Dempster E, Prata D, Shaikh M, Williams I, Schulze K, Marshall N, Walshe M, Allin M, Collier D, Murray R, Bramon. The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychological Medicine. 2009;39(11):1783-97. IF: 5.5
- Costafreda SG, Fu CH, Picchioni M, Kane F, McDonald C, Prata DP, Kalidindi S, Walshe M, Curtis V, Bramon E, Kravariti E, Marshall N, Toulopoulou T, Barker GJ, David AS, Brammer MJ, Murray RM, McGuire PK. Increased inferior frontal activation during word generation: A marker of genetic risk for schizophrenia but not bipolar disorder? Human Brain Mapping. 2009;30(10):3287-98. IF: 7.1
- Prata DP, Mechelli A, Fu C, Picchioni M, Toulopoulou T, Bramon E, Walshe M, Murray R, Collier DA, McGuire. Epistasis between the DAT 3’UTR VNTR and COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America (PNAS).2009;106(32):13600-5. IF: 10.4
- Mechelli A, Tognin S, McGuire PK, Prata D, Sartori G, Fusar-Poli P, De Brito S, Hariri AR, Viding E. Genetic Vulnerability to Affective Psychopathology in Childhood: A Combined Voxel-Based Morphometry and Functional Magnetic Resonance Imaging Study. Biological Psychiatry. 2009; 66(3): 231-237. IF: 10
- Prata DP, Breen G, Osborne S, Munro J, St. Clair D and Collier DA. An association study of the Neuregulin 1 gene, Bipolar Affective Disorder and Psychosis. Psychiatric Genetics. 2009;19(3):113-6. IF: 2.4
- Prata DP, Mechelli A, Fu C, Picchioni M, Kane F, Kalidindi S, McDonald C, Howes O, Kravariti E, Demjaha A, Toulopoulou T, Diforti M, Murray R, Collier DA, McGuire. Opposite effects of COMT Val158Met on cortical function in healthy subjects and patients with Schizophrenia. Biological Psychiatry. 2009;65(6):473-80. IF: 9.5
- Prata DP, Mechelli A, Fu C, Picchioni M, Kane F, Kalidindi S, McDonald C, Kravariti E, Toulopoulou T, Miorelli A, Murray R, Collier DA, McGuire. Effect of disrupted-in-schizophrenia-1 on pre-frontal cortical function. Molecular Psychiatry. 2008 Oct 13(10): 915-917 – which was featured as IMAGE in Molecular Psychiatry. 2008;13(10):909. IF: 14.0
- Prata D, Breen G, Osborne S, Munro J, St. Clair D and Collier DA. Association of DAO and G72(DAOA)/G30 genes with Bipolar Affective Disorder. American Journal of Medical Genetics- Part B (Neuropsychiatric Genetics).2008;147B(6):914-7. IF: 4.5
- Mechelli A, Prata DP, Fu CH, Picchioni M, Kane F, Kalidindi S, McDonald C, Demjaha A, Kravariti E, Toulopoulou T, Murray R, Collier DA, McGuire PK. The effects of neuregulin1 on brain function in controls and patients with schizophrenia and bipolar disorder. Neuroimage. 2008;42(2):817-26. IF: 6.9
- Prata DP, Breen G, Munro J, Sinclair M, Osborne S, Li T, Kerwin R, St Clair D, Collier DA. Bipolar 1 Disorder is not associated with the RGS4, PRODH, COMT and GRK3 genes. Psychiatric Genetics. 2006;16(6):229-30. IF: 2.3
- Prata D*, Breen G*, Osborne S, Munro J, Sinclair M, Li T, Staddon S, Dempster D, Sainz R, Arroyo B, Kerwin RW, St Clair D, Collier DA. Association of the Dysbindin gene with Bipolar Affective Disorder. American Journal of Psychiatry. 2006;163(9):1636-8.* Equal contribution. IF: 14.4
- Martins D & Prata D. A depressão está nos genes? Uma apreciação das bases genéticas e moleculares da depressão major. In A promoção da saúde mental e a prevenção da depressão e suicídio: foco estratégico na integração da saúde mental nos cuidados de saúde primários. EUTIMIA. Lisboa. In press.
- Martins D & Prata D. A suicidalidade está nos genes? Uma visão geral das bases genéticas e moleculares da suicidalidade. In A promoção da saúde mental e a prevenção da depressão e suicídio: foco estratégico na integração da saúde mental nos cuidados de saúde primários. EUTIMIA. Lisboa. In press.
- Martins D & Prata D. Um cérebro deprimido? Alterações neuroimagiológicas na depressão major. In A promoção da saúde mental e a prevenção da depressão e suicídio: foco estratégico na integração da saúde mental nos cuidados de saúde primários. EUTIMIA. Lisboa. In press.
- E-Research Methods Working Group. E-Research Methods (online material). 2014. King’s College London. UK.
- Prata DP. 2014. Biological basis of schizophrenia. In II Congresso de Reabilitação e Inclusão na Saúde Mental (Congress on rehabilitation and inclusion in Mental Health). University of Coimbra, Portugal.
- Prata DP. 2014. Biological basis of cognition in schizophrenia. In II Congresso de Reabilitação e Inclusão na Saúde Mental(Congress on rehabilitation and inclusion in Mental Health). University of Coimbra, Portugal.
- Prata DP. 2008. Effect of Dopamine Regulating Genes on Regional Brain Function during Verbal Fluency in Controls and in Patients with Schizophrenia. PhD Thesis. King’s College London. UK.